Barclays’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-100,427
| Closed | -$1.31M | – | 5043 |
|
|
2025
Q4 | $1.31M | Sell |
100,427
-6,682
| -6% | -$79.8K | ﹤0.01% | 3248 |
|
|
2025
Q3 | $780K | Sell |
107,109
-10,425
| -9% | -$70.5K | ﹤0.01% | 3518 |
|
|
2025
Q2 | $630K | Buy |
117,534
+44,901
| +62% | +$218K | ﹤0.01% | 3628 |
|
|
2025
Q1 | $388K | Sell |
72,633
-25,187
| -26% | -$176K | ﹤0.01% | 3683 |
|
|
2024
Q4 | $875K | Buy |
97,820
+5,169
| +6% | +$54.9K | ﹤0.01% | 3462 |
|
|
2024
Q3 | $1.02M | Buy |
92,651
+38,321
| +71% | +$426K | ﹤0.01% | 3349 |
|
|
2024
Q2 | $494K | Sell |
54,330
-80,877
| -60% | -$790K | ﹤0.01% | 3056 |
|
|
2024
Q1 | $1.9M | Buy |
135,207
+85,793
| +174% | +$1.07M | ﹤0.01% | 2610 |
|
|
2023
Q4 | $380K | Buy |
49,414
+40,996
| +487% | +$227K | ﹤0.01% | 4043 |
|
|
2023
Q3 | $62.8K | Sell |
8,418
-592
| -7% | -$5.05K | ﹤0.01% | 3773 |
|
|
2023
Q2 | $75.1K | Sell |
9,010
-23,987
| -73% | -$277K | ﹤0.01% | 3674 |
|
|
2023
Q1 | $439K | Buy |
+32,997
| New | +$446K | ﹤0.01% | 3357 |
|
|
2021
Q3 | – | Sell |
-885
| Closed | -$11K | – | 4736 |
|
|
2021
Q2 | $11K | Sell |
885
-5,269
| -86% | -$68.4K | ﹤0.01% | 4604 |
|
|
2021
Q1 | $107K | Buy |
6,154
+1,732
| +39% | +$31.3K | ﹤0.01% | 3971 |
|
|
2020
Q4 | $57K | Buy |
4,422
+2,962
| +203% | +$52.8K | ﹤0.01% | 4359 |
|
|
2020
Q3 | $54K | Sell |
1,460
-192
| -12% | -$7.61K | ﹤0.01% | 4557 |
|
|
2020
Q2 | $64K | Buy |
+1,652
| New | +$58.8K | ﹤0.01% | 4793 |
|
|
2018
Q2 | – | Sell |
-30
| Closed | -$3K | – | 6955 |
|
|
2018
Q1 | $3K | Buy |
+30
| New | +$3K | ﹤0.01% | 6846 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | – | – | 6591 |
|
|
2016
Q2 | $0 | Buy |
+1
| New | +$301 | ﹤0.01% | 6314 |
|
Barclays's ATXS Position: Q1 2026 in Review
Barclays sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 100,427 shares — an estimated $1.31M sold.
Barclays first reported a position in ATXS in Q2 2016 and held it in 19 quarters. The position peaked at $1.9M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Barclays reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Barclays sold 100,427 Astria Therapeutics shares in Q1 2026, an estimated $1.31M.
- Barclays first reported a position in Astria Therapeutics in Q2 2016 and held it in 19 quarters.
- Barclays's Astria Therapeutics position peaked at $1.9M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.